

1/64




FIG. 1A

2/64




FIG. 1B




FIG. 1C




FIG. 2A




FIG. 2B

6/64




FIG. 2C




FIG. 2D

8/64




FIG. 2E




FIG. 2F




FIG. 26




FIG. 2H

12/64




FIG. 2I

13/64




FIG. 2J




FIG. 2K




FIG. 2L




FIG. 3

17/64




FIG. 4

18/64

ATGGTCAGCTACTGGGACACCGGGGTCCCTGCTGTGCGCGCTGCTCAGCTGTCIGC
TTCTCACAGGATCTAGTTCGGGAAGTGATACCGGTAGACCTTTCTGTAGAGATGTA
CAGTGAAATCCCGAATTAACACATGACTGAAGGAAGGAGCTCGTCATTCC
CTGCCGGTTACGTACCTAACATCACTGTTACTTTAAAAGTTTCCACTTGAC
ACTTIGATCCCTGATGGAAAACGCATAATCTGGGACAGTAGAAAGGGCTTCATC
ATAATCAATGCAACGTACAAAGAAATAGGGCTTCTGACCTGTGAAGCAACAGTC
AATGGCATTGTATAAGACAAACTATCTCACACATCGACAACCAATACAATC
ATAGATGTGGTTCCTGAGTCCGTCTCATGGAAATGAACTATCTGTTGGAGAAAAGC
TTGTCTTAATTGTACAGCAAGAACTGAACCTAAATGTGGGATTGACTTCAACTG
GGAATACCTTCTTCGAGCATCAGCATAAGAACTTGTAACCGAGACCTAAA
AACCAGTCTGGGAGTGAGATGAAGAAATTTTGTAGCACCTTAACCTATAGATGG
TGTAACCCGGAGTGACCAAGGATTGTACACCTGTGCAGCATCCAGTGGGCTGAT
GACCAAGAAAGACAGCACATTGTGAGGGTCCATGAAAGGACAAACTCACA
CATGCCACCGTGCCAGCACCTGAACCTCTGGGGACCGTCAAGTCTTCTCTT
CCCCCAAACCAAGGACACCTCATGATCTCCGGACCCCTGAGGTCACATG
CGTGGTGGTGGACGTGAGCCACGAGACCCCTGAGGTCAAGTTCAACTGGTACGT
GGACGGCGTGGAGGTGCATAATGCCAAGACAAGCCGCGGAGGAGCAGTACA
ACAGCACGTACCGTGTGGTCAAGCTCCTCACCGTCCCTGCACCAAGGACTGGCTGA
ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAGCCCTCCAGCCCCCATCG
AGAAACCATCTCCAAGCCAAAGGGCAGCCCGAGAACCAAGGTGTACACC
CTGCCCCCATCCGGGATGAGCTGACCAAGAACCAAGGTCAAGCTGACCTGCCCTG
GTCAAGGGCTTCTATCCAGCGACATCGCCGTGGAGTGGAGAGCAATGGGCAG
CCGGAGAACAACTACAAGACCAAGCCCTCCCGTGTGCTGGAATCCGACGGCTCCTTC
TTCCTCTACAGCAAGCTCACCGTGGAACAAGAGCAGGTGGCAGCAGGGGAACGTC
TTCTCATGCTCCGTGATGCGATGAGGCTCTGCACAACCACTACACGCAAGAGC
CTCTCCCTGTCTCCGGTAAATGA

FIG.5




FIG. 6










	SUBJECT 1: 44 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 2: 40 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 3: 36 WEEKS POST-AAV2.7m8-AFLIBERCEPT
BASELINE OCT	 	 	 
LATEST OCT	 	 	 
BCVA CHANGE FROM BASELINE, ETDRS LETTERS	+3	-9	-6
IVT IN 8 MONTHS PRIOR TO THIS STUDY, ⁿ	5	6	6
RESCUE IVT DURING THIS STUDY, ⁿ	0	0	0

FIG. 7A











	SUBJECT 4: 32 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 5: 28 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 6: 28 WEEKS POST-AAV2.7m8-AFLIBERCEPT
BASELINE OCT	 	 	 
LATEST OCT	 	 	 
BCVA CHANGE FROM BASELINE, ETD RS LETTERS	+5	+1	-3
IVT IN 8 MONTHS PRIOR TO THIS STUDY, n	6	6	8
RESCUE IVT DURING THIS STUDY, n	0	0	0

FIG. 7B




FIG. 8











	SUBJECT 1: 52 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 2: 48 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 3: 44 WEEKS POST-AAV2.7m8-AFLIBERCEPT
BASELINE OCT	 	 	 
LATEST OCT	 	 	 
BCVA CHANGE FROM BASELINE, EIDRS LETTERS	+7	-6	-7
CST CHANGE FROM BASELINE, µm	+32	-29	-55

FIG. 9A












	SUBJECT 4: 44 WEEKS* POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 5: 40 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 6: 40 WEEKS POST-AAV2.7m8-AFLIBERCEPT
BASELINE OCT	 	 	 
LATEST OCT	 	 	 
BCVA CHANGE FROM BASELINE, ETDRS LETTERS	+5*	-2	-3
OCT CHANGE FROM BASELINE, μm	-117*	+4	+12

FIG. 9B




FIG. 10

26/64




FIG. 11




FIG. 12












	SUBJECT 1: 24 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 2: 24 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 3: 24 WEEKS POST-AAV2.7m8-AFLIBERCEPT
BASELINE OCT	 	 	 
LATEST OCT	 	 	 
BCVA CHANGE FROM BASELINE, ETDRS LETTERS	-4	-1	-19*
CST CHANGE FROM BASELINE, µm	-8	-38	-11*
RESCUE IVT INJECTIONS, n	0	0	3*

FIG. 13A




	SUBJECT 4: 24 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 5: 24 WEEKS POST-AAV2.7m8-AFLIBERCEPT	SUBJECT 6: 24 WEEKS POST-AAV2.7m8-AFLIBERCEPT
BASELINE OCT			
LATEST OCT			
BCVA CHANGE FROM BASELINE, ETDRS LETTERS	-14	-7*	+16
CST CHANGE FROM BASELINE, µm	-16	-33*	-61
RESCUE IVT INJECTIONS, n	0	3*	0

FIG. 13B




FIG. 14




FIG. 15A





FIG. 15B






FIG. 16A




FIG. 16B




FIG. 17A




FIG. 17B




FIG. 18A





FIG. 18B



9

G




FIG. 20A




FIG. 20B

43/64




FIG. 21A




FIG. 21B

SUBSTITUTE SHEET (RULE 26)




FIG. 22A




FIG. 22B





FIG. 22C






FIG. 23A

50/64




FIG. 23B




FIG. 24A




FIG. 24B




FIG. 25A





FIG. 25B



26

56/64




FIG. 27A




FIG. 27B

57/64




FIG. 28A




FIG. 28B




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34